A. Sologuren

Model‐informed pediatric development applied to bilastine: Analysis of the clinical PK data and confirmation of the dose selected for the target population

J. Lukas, Mónica Rodríguez, S. Schmidt, 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency

K. Lasseter, A. Sologuren, A. La Noce, 2013, Clinical Drug Investigation.

Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double‐blind, parallel‐group study

C. Bachert, I. Agache, P. Kuna, 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Pharmacokinetic-Pharmacodynamic Modelling of the Antihistaminic (H1) Effect of Bilastine

N. Jauregizar, L. Fuente, M. L. Lucero, 2009, Clinical pharmacokinetics.

Model Informed Pediatric Development Applied to Bilastine: Ontogenic PK Model Development, Dose Selection for First Time in Children and PK Study Design

J. Lukas, Mónica Rodríguez, V. Vozmediano, 2017, Pharmaceutical Research.

Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions

A. Sologuren, C. Campo, Amalia Leceta, 2021, Drugs in context.

Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria.

A. Sologuren, L. Labeaga, S. Fernández, 2018, Allergy and asthma proceedings.

Lack of Significant Effect of Bilastine Administered at Therapeutic and Supratherapeutic Doses and Concomitantly With Ketoconazole on Ventricular Repolarization: Results of a Thorough QT Study (TQTS) With QT‐Concentration Analysis

B. Tyl, R. Valiente, A. Sologuren, 2012, Journal of clinical pharmacology.

Bilastine in allergic rhinoconjunctivitis and urticaria: a practical approach to treatment decisions based on queries received by the medical information department

R. Valiente, A. Sologuren, L. Labeaga, 2017, Drugs in context.

Effects of Lerisetron, a New 5-HT3 Receptor Antagonist, on Ipecacuanha- induced Emesis in Healthy Volunteers

Jeffery S. Smith, R. Valiente, A. Sologuren, 2002, Arzneimittelforschung.

Lack of Significant Effect of Bilastine Administered at Therapeutic and Supratherapeutic Doses and Concomitantly With Ketoconazole on Ventricular Repolarization: Results of a Thorough QT Study (TQTS) With QT‐Concentration Analysis

B. Tyl, R. Valiente, A. Sologuren, 2012, Journal of clinical pharmacology.